Skin Cancer Drug Elesclomol Moves Closer to Production

by: cancercompass

Late-stage study data presented this month by Synta Pharmaceuticals Inc. reinforces the likelihood that the company will produce its skin cancer drug elesclomol, reports the Associated Press.

Synta Pharmaceuticals Inc. is testing elesclomol, in combination with paclitaxel, to help treat patients with the skin cancer known as metastatic melanoma.

The company says additional data revealed that lactate dehydrogenase (LDH) could help predict how well elesclomol will work in improving survival outcomes. LDH is an enzyme that plays an important role in cell energy production.

In addition, the company released a statement that said the results show "there are clear signs" the drug will benefit patients with normal LDH. To date, adverse effects have been restricted to patients with high LDH.